“Microdosing” sounds precise. It isn’t. There’s no medical definition, no trial and no label behind it, only a marketing word for taking less tirzepatide than Zepbound’s label uses. That doesn’t make the idea foolish. It means the questions are different: what are you trying to achieve, and can anyone measure your dose accurately?
What people mean by “microdosing” tirzepatide
Online programs use the word in two ways. Some mean doses below the label’s steps. Others mean staying on a low dose much longer than the label’s usual climb. Most of it is sold as compounded tirzepatide, the pharmacy-made version explained in compounded tirzepatide.
A 2026 brief report for nurse practitioners named the main reasons people try it: fewer stomach side effects, wanting to lose only a few pounds (what it calls “vanity weight”), and cost [8]. The same report warns about dosing errors, compounded vials and shared pens. It reviews practice; it doesn’t report trial data. The wider idea, across semaglutide and other GLP-1s, is covered in microdosing GLP-1s.
No trial has tested it
Right now, no randomized trial has tested tirzepatide at doses below the label for weight, metabolic health or aging. A PubMed search for randomized trials of low-dose or microdosed tirzepatide turned up none on this question. Every effect size you’ll see quoted comes from trials of labeled doses.
Those trials do tell you something useful about low doses. SURMOUNT-1 gave 2,539 adults without diabetes tirzepatide at 5, 10 or 15 mg a week, or placebo, for 72 weeks [6]. Even the lowest dose did a lot.
| Dose pattern | Where it comes from | Studied in a trial? | Result |
|---|---|---|---|
| 2.5 mg weekly for 4 weeks | Zepbound label: starting dose | Yes, as a first step only | Not approved for maintenance [2] |
| 5 mg weekly | Zepbound label: lowest maintenance dose | Yes, SURMOUNT-1 | −15.0% at 72 weeks [6] |
| 10 mg weekly | Zepbound label: maintenance dose | Yes, SURMOUNT-1 | −19.5% at 72 weeks [6] |
| 15 mg weekly | Zepbound label: maximum dose | Yes, SURMOUNT-1 | −20.9% at 72 weeks [6] |
| Below the label’s doses (“microdose”) | Marketing term | No | Unknown |
| Staying on a low dose indefinitely | Some programs’ protocols | No | Unknown; the label allows staying at least 4 weeks per step |
SURMOUNT-1 used Eli Lilly’s product and was funded by Eli Lilly. No row here tells you how a compounded product performs.
What the Zepbound label actually says about low doses
The label is clear on one thing: “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage” [2]. After four weeks, the label moves to 5 mg, and it allows increases in 2.5 mg steps “after at least 4 weeks on the current dose.” Maintenance doses are 5, 10 or 15 mg, and 15 mg is the maximum.
The label also leaves room for tolerability. It tells prescribers to “consider treatment response and tolerability when selecting the maintenance dosage,” and if a maintenance dose isn’t tolerated, to “consider a lower maintenance dosage” [2]. Read closely, the lowest maintenance dose it names is 5 mg. So the label’s own answer to side effects is a slower climb or a lower labeled dose, chosen by a prescriber, not a dose below the label. The label’s starting-dose facts are laid out in compounded tirzepatide starting dose.
A slower climb isn’t the same thing as a microdose
These two ideas get mixed up, and the difference matters. Staying longer on a labeled step before moving up fits the label, which sets a minimum of four weeks per step, not a maximum [2]. Settling on 5 mg as a long-term dose fits it too. Both use doses that were tested.
Taking less than 2.5 mg, or staying on 2.5 mg as if it were a maintenance dose, is outside what the label covers. That’s the part with no trial behind it. If a program describes its plan as “microdosing,” ask which of these it really means. The answer changes how much evidence stands behind it.
Why people try it: side effects and cost
Side effects are real, and they’re dose-related. In the label’s pooled weight trials, nausea affected 25% of people on 5 mg and 28% to 29% on the higher doses, against 8% on placebo [2]. Diarrhea ran 19% to 23%, and vomiting 8% to 13%. In SURMOUNT-1, side effects led 4.3% of people on 5 mg and up to 7.1% on higher doses to stop, against 2.6% on placebo [6].
Severe stomach reactions were less common but also rose with dose: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, against 1% on placebo [2]. Most side effects showed up while the dose was climbing. That pattern is the honest case for going slowly. It isn’t evidence that a dose below the label works.
Cost is the other driver. Through LillyDirect, Zepbound vials and KwikPens list at $299 a month for 2.5 mg and $399 for 5 mg as of this update [5]. Higher doses are $449 a month when you refill within 45 days. A smaller dose of a cheaper compounded product looks appealing next to those numbers. Before you decide, compare the price at the dose you’d actually stay on; what compounded tirzepatide costs breaks that down.
Brand or compounded for a low dose: the trade-off
Brand Zepbound comes only in its labeled strengths, from 2.5 mg up to 15 mg [2]. A dose below 2.5 mg doesn’t exist as a brand product, so nearly every “microdose” plan uses compounded tirzepatide from a vial.
That puts the plan under the compounding rules. Since March 2025, a pharmacy may copy an approved drug only for an individual patient, and copies beyond four prescriptions a month need a prescriber to document a “significant difference” for that patient [1]. Whether a nonstandard dose meets that bar is a judgment made one patient at a time, in your prescriber’s notes. A program’s marketing can’t make it for you. The rules in full are in is compounded tirzepatide still available.
The dose-accuracy problem
Compounded multi-dose vials are where FDA has seen measuring mistakes. FDA has received reports of adverse events, “some requiring hospitalization,” linked to patients and even clinicians measuring the wrong dose of compounded semaglutide [3]. It has also received reports tied to compounded semaglutide or tirzepatide prescribed “in doses beyond what is in the FDA-approved drug label.” A nonstandard dose drawn from a vial is the kind of setup where that happens.
There’s also the question of what’s in the vial. FDA does not review compounded drugs “for safety, effectiveness or quality before they are marketed” [3]. If the vial’s strength is off, a microdose is off too, and you can’t tell by looking. FDA also says to use a multi-dose vial within 28 days of first use, even if the compounder’s label says longer.
Who shouldn’t take tirzepatide at any dose
A smaller dose doesn’t change who the drug is wrong for. Zepbound’s label rules it out for anyone with a personal or family history of medullary thyroid cancer or MEN 2, or a known serious allergy to tirzepatide [2]. It “may cause fetal harm,” so the label says to stop when pregnancy is recognized. It can also make birth-control pills less reliable, and the label advises switching to a non-oral method or adding a barrier method for a time. Tell your prescriber about any pancreatitis, gallbladder or kidney history before you start.
Longevity claims for low-dose tirzepatide
No study shows that tirzepatide at any dose extends lifespan. The closest thing to a long-run benefit on a label is Mounjaro’s August 2026 indication to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk [4]. That came from full doses in people with diabetes, not from low doses in healthy people.
Programs that market microdosing for “longevity,” focus or general wellness are making claims no trial has tested. That’s worth knowing before you pay for a protocol, however reasonable the pitch sounds.
If you’re considering it: questions for your prescriber
- What’s the goal: a few pounds, fewer side effects, metabolic health? How will we know if it’s working?
- Brand Zepbound at a labeled dose, or a compounded product? Why?
- If compounded, which pharmacy makes it, and how is the dose measured and checked?
- What monitoring comes with it, and how often?
- What happens if I stop? In SURMOUNT-4, people switched to placebo regained 14.0% of their weight over a year [7].
- What will this cost per month at the dose I’d actually stay on?
That fifth question matters for long-run thinking. Tirzepatide works while you take it, and SURMOUNT-4 showed most of the benefit fades after stopping [7]. A low dose you can stay on for years may suit some people. Whether it does anything at all below the label is the part nobody has measured. For how a compounded product stacks up against the brand overall, see compounded tirzepatide vs Zepbound.
What microdose programs cost
Programs that sell “microdose” tirzepatide list it at $119–$249 a month as of this update. Several others offer a microdose plan but don’t publish its price. The table shows the monthly figure on each program’s own site and how it bills. It doesn’t show dose amounts, because the dose is your prescriber’s decision.
| Provider | Product | Monthly price | Billing or minimum |
|---|---|---|---|
| LTTLPartner | Compounded tirzepatide, microdose plan | $149/mo | Monthly, or prepay for a lower rate |
| AgelessRx | Compounded tirzepatide with glycine, microdosing | $159/mo | Billed every 2 months after an intro month |
| Luvo HealthPartner | Compounded tirzepatide, microdose plan | $193.92/mo | Every 28 days |
| ShedRxPartner | Compounded tirzepatide, microdose plan | $215.58/mo | Monthly, 2-month minimum |
| BMIMDPartner | Compounded tirzepatide, microdose plan | $249/mo | Month to month, or prepay |
| Midi Health | GLP-1 microdosing | Priced per week | Not stated |
| Enhance MD | Compounded tirzepatide, low dose | Prepay only | 3-month minimum, billed every 12 weeks |
Prices come from each provider’s own site, as a calendar-month cost on the shortest plan; intro offers are not the headline. “Not published” means the price appears only after sign-up.
Also offered by (no standing monthly price published): Maximus, BrightMeds, CoreAge RxPartner, Found.
Notice the overlap with full-dose pricing. Some microdose plans cost about the same as a program’s standard compounded tirzepatide, so a smaller dose doesn’t always mean a smaller bill. AgelessRx bills every two months after its intro month, and ShedRx requires two months up front. Compare every program offering compounded tirzepatide on the compounded tirzepatide providers scorecard.